Lichen planus triggered by
            <scp>CT</scp>
            ‐P13 and recurrence during secukinumab treatment

Maglie, Roberto; Cesare, Antonella Di; Lazzeri, Linda; Pescitelli, Leonardo; Ricceri, Federica; Vannucchi, Margherita; Massi, Daniela; Prignano, Francesca

doi:10.1111/bjd.16003

Cited by 12 publications

(9 citation statements)

References 5 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, TNF blockade is well established for the treatment of PSO but is of no reproducible benefit in CLP. Anti‐TNF‐α blockade has even been reported to induce paradoxical manifestation of LP eruptions in skin and mucosa of single patients 31,32 …”

Section: Discussionmentioning

confidence: 99%

The inflammation in cutaneous lichen planus is dominated by IFN‐ϒ and IL‐21—A basis for therapeutic JAK1 inhibition

Pietschke

Holstein

Meier

et al. 2020

Experimental Dermatology

View full text Add to dashboard Cite

Cutaneous lichen planus (CLP) and psoriasis (PSO) are both common chronic inflammatory skin diseases for which development of new treatments requires the identification of key targets. While PSO is a typical Th17/IL‐17‐disorder, there is some evidence that Th1/IFN‐ɣ dominate the inflammatory process in CLP. Nonetheless, the immunopathogenesis of CLP is not fully explained and key immunological factors still have to be recognized. In this study, we compared the immune signature of CLP lesions with the well‐characterized inflammation present in PSO skin. First, we analysed the histological and immunohistological characteristics of CLP and PSO. Second, we assessed the cytokine expression (IL1A, IL1B, IL4, IL6, IL8, IL10, IL17A, IL19, IL21, IL22, IL23A, IL13, IFNG, TNF, IL12A, IL12B and IL36G) of lesional skin of CLP with PSO by qPCR. Histology revealed a similar epidermal thickness in CLP and PSO. Immunohistochemically, both diseases presented with an inflammatory infiltrate mainly composed by CD3+CD4+ T cells rather than CD3+CD8+. Importantly, mRNA analysis showed a distinct cytokine signature: while levels of IL12B, IL1A, IL6 and IL23 were similar between the two groups, the characteristic PSO‐associated cytokines IL8, IL17A, IL22, IL19 and IL36G were expressed at very low levels in CLP. In contrast, CLP lesional skin was dominated by the expression of IFNG, IL21, IL4, IL12A and TNF. Immunohistochemistry confirmed the dominance of IL‐21, IFN‐ɣ and also pSTAT1 in the dermal infiltrate of CLP, while IL‐17A was more present in PSO. Collectively, this study improves our understanding of the immunological factors dominating CLP. The dominating cytokines and signalling proteins identified suggest that anti‐cytokine therapeutics like JAK inhibitors may be beneficial in CLP.

show abstract

Section: Discussionmentioning

confidence: 99%

The inflammation in cutaneous lichen planus is dominated by IFN‐ϒ and IL‐21—A basis for therapeutic JAK1 inhibition

Pietschke

Holstein

Meier

et al. 2020

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…Recently, we reported a case of oral lichen planus triggered by infliximab-biosimilar CT-P13 that recurred when the patient was switched to SEK 2 . In our case, we did not observed a concomitant candida infection; however, during SEK treatment, the lichenoid eruption extended to the arms, trunk, and legs.…”

mentioning

confidence: 45%

Comment on “Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?”

et al. 2019

View full text Add to dashboard Cite

“…Reported skin related adverse events from phase 3 trials of secukinumab for psoriasis include oral herpes, urticaria, tinea pedis, oral candidiasis, and impetigo, though case reports of other cutaneous reactions have been reported (Table 1), [4,[6][7][8][9][10][11][12][13][14][15][16][17][18]. The Naranjo score is a tool that can help determine the likelihood that a medication in question is responsible for the adverse reaction, which in this case is three (Table 2), [19].…”

Section: Case Discussionmentioning

confidence: 99%

Bullous acral eruption related to secukinumab

Blackcloud

Dupuy²,

Kang³

et al. 2019

Dermatology Online Journal

View full text Add to dashboard Cite

Lichen planus triggered by CT ‐P13 and recurrence during secukinumab treatment

Abstract: (ALCANZA) : an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017; 390:550-66 Funding sources: none.

Cited by 12 publications

References 5 publications

The inflammation in cutaneous lichen planus is dominated by IFN‐ϒ and IL‐21—A basis for therapeutic JAK1 inhibition

The inflammation in cutaneous lichen planus is dominated by IFN‐ϒ and IL‐21—A basis for therapeutic JAK1 inhibition

Comment on “Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?”

Bullous acral eruption related to secukinumab

Contact Info

Product

Resources

About